PDL BioPharma (PDLI) - Eyes focused on Evofem

08:55 EDT 15 Aug 2019 | Edison Investment Research

Edison Investment Research - Pharmaceuticals & healthcare - PDL BioPharma: In June, PDL invested the second and final tranche of $30m ($60m in total) in Evofem, a women’s health company that is preparing to submit an NDA for Amphora, a non-hormonal female contraceptive, in Q419 with approval expected in H120. PDL now owns approximately 29% of the company. Evofem recently released exploratory data from its pivotal AMPOWER trial, which indicated that unlike other contraceptives, Amphora may increase sexual satisfaction, which could give it a marketing edge upon approval. The market opportunity is quite large, with $6.5bn worth of hormonal contraceptives being sold in 2018 according to EvaluatePharma.
ISIN: US69329Y1047

Original Article: PDL BioPharma (PDLI) - Eyes focused on Evofem


More From BioPortfolio on "PDL BioPharma (PDLI) - Eyes focused on Evofem"

Quick Search

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...